



Correction: Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma

Suzette Girgis¹ · Shun Xin Wang Lin² · Kodandaram Pillarisetti² · Arnob Banerjee² · Tara Stephenson² · Xuewen Ma² · Shoba Shetty² · Tong-Yuan Yang² · Brandi W. Hilder² · Qun Jiao² · Brett Hanna² · Homer C. Adams III² · Yu-Nien Sun² · Amarnath Sharma³ · Jennifer Smit² · Jeffrey R. Infante¹ · Jenna D. Goldberg¹ · Yusri Elsayed²

Published online: 1 August 2022
© The Author(s) 2022

Correction: Targeted Oncology
<https://doi.org/10.1007/s11523-022-00893-y>

The co-author name incorrectly published as Homer Adams III should read as Homer C. Adams III.

The original article has been corrected.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction

in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

The original article can be found online at <https://doi.org/10.1007/s11523-022-00893-y>.

✉ Suzette Girgis
SGirgis@its.jnj.com

¹ Janssen Research & Development, 920 Route 202, Raritan, NJ 08869, USA

² Janssen Research & Development, Spring House, PA, USA

³ Janssen Research & Development, Tokyo, Japan